对氨酸激酶抑制剂与HER2和HER4受体进行比较对接分析
Priyanka Sonar1, Karimunnisa Shaikh1, Sangeeta Ballav2
1Department of Pharmaceutics, Progressive Education Society's, Modern College of Pharmacy, Nigdi, Pune, M.S, India.
Bioinformation
|September 1, 2023
概括
拉帕提尼布显示出作为HER2和HER4受体氨酸激酶 (RTKs) 的双重抑制剂的潜力,这在乳腺癌进展中至关重要. 这项研究强调了拉帕提尼布的作用.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 铁酶受体,特别是像EGFR这样的ERBB受体,在乳腺癌的生长和转移中发挥着关键作用.
- 过度表达HER2和HER4与人类乳腺癌的发展有显著关联.
- 针对受体氨酸激酶 (RTKs) 的小分子抑制剂提供了针对癌症的治疗策略.
研究的目的:
- 为了比较评估结构相似的氨酸激酶抑制剂 (TKI) 对HER2和HER4受体的抑制潜力.
- 使用in-silico方法研究这些TKI与HER2和HER4的分子相互作用和结合模式.
主要方法:
- 使用FlexX软件的in-silico分子对接来评估TKI与HER2和HER4的结合.
- 使用BIOVIA发现工作室可视化器分析了对接的复杂交互配置文件.
- 对比了各种小分子TKIs的结合得分,包括拉帕提尼布,蒂沃赞尼布,埃尔洛提尼布,盖菲提尼布,克里佐提尼布和谢里蒂尼布.
主要成果:
- 在测试的化合物中,拉巴提尼布表现出最高的结合得分 (HER2 - 32.36 kcal/mol和HER4 - 35.76 kcal/mol).
- 分子对接分析提供了关于拉帕提尼布与HER2和HER4的结合模式和相互作用的见解.
- 拉帕提尼布被确定为HER2和HER4受体氨酸激酶的强有力的抑制剂.
结论:
- 拉帕提尼布是抑制HER2和HER4的有希望的候选者,这表明它在治疗由这些RTK驱动的乳腺癌方面的潜力.
- 这些发现支持进一步调查Lapatinib在乳腺癌中抑制EGFR家族蛋白质的有效性.
- 这项研究为开发针对乳腺癌HER2和HER4的向疗法提供了计算基础.
相关概念视频
01:26Receptor Tyrosine Kinases
13.1K
Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
13.1K
01:27Transducer Mechanism: Enzyme-Linked Receptors
2.5K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.5K
02:57Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
01:00Enzyme-linked Receptors
78.7K
Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
78.7K